Core Viewpoint - Reap Bio (300119.SZ) has received a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for a multi-strain inactivated vaccine targeting avian diseases, marking a significant advancement in the poultry vaccine market in China [1] Group 1: Product Approval - The new veterinary drug is a four-in-one inactivated vaccine for Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and infectious bursal disease [1] - The approval fills a market gap for QX-type infectious bronchitis virus multi-strain vaccines in China [1] Group 2: Company Positioning - The product reflects the company's forward-looking layout and innovative capabilities in the poultry vaccine sector [1] - The new vaccine enhances the company's poultry vaccine product line, helping to solidify its leading position in the industry [1] - The introduction of this vaccine is expected to provide a new growth point for the company's performance [1]